{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-22-000055","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.703887+00:00","generated_at":"2026-06-21T05:29:23.334698+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Moderna and Merck report Phase 2b mRNA cancer vaccine met primary endpoint in melanoma, reducing recurrence risk by 44%","bullets":["mRNA-4157/V940 + KEYTRUDA reduced risk of recurrence or death by 44% vs KEYTRUDA alone (HR=0.56, p=0.0266) in stage III/IV melanoma.","First randomized trial evidence for an mRNA cancer treatment; companies plan Phase 3 in melanoma in 2023 and expansion to other tumor types.","Serious treatment-related AEs: 14.4% in combination arm vs 10% with KEYTRUDA alone.","Merck and Moderna share costs and profits equally under worldwide collaboration announced in October."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-22-000055","json":"https://secwatch.observer/filing/0001682852-22-000055.json","markdown":"https://secwatch.observer/filing/0001682852-22-000055.md","text":"https://secwatch.observer/filing/0001682852-22-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285222000055/0001682852-22-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285222000055/mrna-20221213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:29:23.334698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}